COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry
Written By
Partner
Belgium
As co-head of our International Life Sciences & Healthcare group and head of Bird & Bird's Regulatory, Public & Administrative Law group in Brussels, I provide cutting edge strategic and regulatory advice to our life sciences clients and represent them in litigation.
Partner
UK
I am a partner in our international Intellectual Property Group and co-head of our International Life Sciences & Healthcare Group. I'm based in London.
Partner
UK
As one of our firm's most experienced intellectual property partners, specialising in transactional IP matters, I offer a wealth of knowledge to businesses at the cutting edge of research, development and technology, in a variety of sectors for which IP is of prime importance.
Related
Practices
Sectors
Trending Topics
Regions
COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located. This update aims to provide guidance on the responses of EU and Asia-Pac regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.
Latest insights
More Insights
Hello there regulation! Implications operators of self-consumption facilities must now deal with following the latest ECJ judgement
Dec 10 2024
